ACLXArcellx, Inc.

$7B

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M-81.0% YoY

Gross Profit

-$30M-609.0% margin

Operating Income

-$62M-1248.3% margin

Net Income

-$56M-1127.1% margin

EPS (Diluted)

$-0.99

QoQ Revenue Growth

-34.5%

Cash Flow

Operating Cash Flow

-$49M

Free Cash Flow

-$50M

Stock-Based Comp.

$18M

Balance Sheet

Total Assets

$656M

Total Liabilities

$215M

Stockholders' Equity

$441M

Cash & Equivalents

$79M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$26M	-81.0%
Gross Profit	-$30M	$26M	-215.8%
Operating Income	-$62M	-$34M	-83.8%
Net Income	-$56M	-$26M	-115.6%

ACLX Q3 2025 Earnings — Arcellx, Inc. Revenue & Financial Results | Market Cap Arena